ApoE and Aβ1–42 interactions
- 417 Downloads
Abnormalities in the processing of amyloid precursor protein to amyloid-β (Aβ) are causal factors, and the presence of the ε4 allele of apolipoprotein E (apoE) is the primary risk factor for Alzheimer’s disease (AD). Based, at least in part, on these genetics, the potential structural and functional interactions between these two proteins are the focus of our research. To understand the nature of the physical interactions between apoE and Aβ, we initially utilized gel-shift assays to demonstrate that native apoE2 and E3 (associated with lipid particles) form an SDS-stable complex with Aβ that is more abundant than the apoE4:Aβ complex. We further demonstrated that exogenous apoE3 but not E4 prevents Aβ-induced neurotoxicity by a process that requires apoE receptors. In addition, both exogenous apoE3 and E4 prevent Aβ-induced, glial-mediated inflammation, also via a process that requires apoE receptors. These functional effects all occur at a molar ratio of apoE to Aβ of 1:30. Because the biological activities for both apoE and Aβ are profoundly influenced by their isoform and conformation, respectively, we further investigated the idea that apoE3 and E4 differentially interact with particular aggregation species of Aβ1–42. Our overall hypothesis is that apoE has two general functions in relation to Aβ. First, apoE interacts with oligomeric Aβ via an apoE receptor-mediated process to inhibit neurotoxicity and neuroinflammation (apoE3>apoE4) a process possibly related to binding and clearance of apoE3:oligomer complexes. Second, apoE facilitates the deposition of Aβ as amyloid (apoE4 \s>apoE3). We will continue to investigate the effect of apoE isoform and Aβ conformation on the structural and functional interactions between these two proteins in relation to the pathogenesis of AD.
Index EntriesApolipoprotein E amyloid-beta neuroinflammation neurotoxicity Alzheimer’s disease Aβ oligomers
Unable to display preview. Download preview PDF.
- Chartier-Harlin M. C., Parfitt M., Legrain S., Perez-Tur J., Brousseau T., Evans A., et al. 1994. Apolipoprotein E, ε4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet. 3, 569–574.PubMedCrossRefGoogle Scholar
- Evans K. C., Berger E. P., Cho C. G., Weisgraber K. H., and Lansbury P. T. (1995) Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 92, 763–767.PubMedCrossRefGoogle Scholar
- Ghiso J., Matsubara E., Koudinov A., Choi-Miura N. H., Tomita M., Wisniewski T., and Frangione B. (1993) The cerebrospinal-fluid form of Alzheimer’s amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293, 27–30.PubMedGoogle Scholar
- Houlden H., Crook R., Duff K., Collinge J., Roques P., Rossor M., and Hardy J. (1993) Confirmation that the ApoE4 allele is associated with late onset, familial Alzheimer’s disease. Neurodegeneration 2, 283–286.Google Scholar
- Irizarry M. C., Cheung B. S., Rebeck G. W., Paul S. M., Bales K. R., and Hyman B. T. (2000) Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP (V717F) transgenic mice. Acta Neuropathol. (Berl.) 100, 451–458.CrossRefGoogle Scholar
- LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., and Frail D. E. (1994) Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269, 23404–23406.Google Scholar
- LaDu M. J., Pederson T. M., Frail D. E., Reardon C. A., Getz G. S., and Falduto M. T. (1995) Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J. Biol. Chem. 270, 9030–9042.Google Scholar
- Oda, T., Wals P., Osterburg H. H., Johnson S. A., Pasinetti G. M., Morgan T. E., et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 136, 22–31.PubMedCrossRefGoogle Scholar
- Small D. H. (1998) The amyloid cascade hypothesis debate: emerging consensus on the role of A beta and amyloid in Alzheimer’s disease, in The Sixth International Conference on Alzheimer’s disease, Vol. 5, The Parthenon Publishing Group, Amsterdam, The Netherlands, pp. 301–304.Google Scholar
- Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., and Roses A. D. (1993) Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977–1981.PubMedCrossRefGoogle Scholar
- Sullivan P. M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R. L., et al. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272, 17972–17980.PubMedCrossRefGoogle Scholar